Oral small molecule GLP-1 receptor agonist
Danuglipron 200 mg oral twice daily
DANU_PO_200MG_BID
Related
- All doses pooled: Danuglipron tablet
- Danuglipron 80 mg oral twice daily
- Danuglipron 140 mg tablet twice daily
- Danuglipron 40 mg oral twice daily
- Danuglipron 120 mg oral twice daily
- Danuglipron 160 mg oral twice daily
- Danuglipron 2.5 mg tablet twice daily
- Danuglipron 10 mg tablet twice daily
- Danuglipron 3 mg tablet
- Danuglipron 10 mg tablet
- Danuglipron 30 mg tablet
- Danuglipron 100 mg tablet
- Danuglipron 300 mg tablet
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.41 (0.38 to 37.83) | 0.26 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 12.84 (2.86 to 87.69) | 0.10 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 7.81 (2.67 to 28.37) | 0.20 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.77 (2.03 to 44.64) | 0.29 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.54 (0.84 to 20.04) | 0.28 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.35 (0.29 to 7.10) | 0.61 |